Sales of bioAffinity's CyPath® Lung test for lung cancer reached a new high in Q3 2025, representing a 95% increase over the ...

Affinity Technologies, Inc. ( ($BIAF) ) has issued an update. On October 16, 2025, bioAffinity Technologies, Inc. announced it received a ...

Di condition of our lungs fit reveal many tins about our wider health. Luckily, you fit also get dem into beta shape.

Affinity Technologies shares surged over 20% pre-market following a strong third-quarter sales update for its lung cancer ...

Affinity Technologies' stock surged after a patent notice and Nasdaq compliance update but slipped in after-hours trading.

Investing.com -- Bioaffinity Technologies Inc (NASDAQ:BIAF) stock soared 79% in premarket trading Friday after the biotechnology company released three new case studies highlighting the effectiveness ...

Affinity Technologies, Inc. ( (BIAF) ) has issued an update. On October 15, 2025, bioAffinity Technologies announced it has regained compliance with Nasdaq’s listing requirements, ensuring its common ...

Personalis (PSNL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

Data from the Phase Ib Beamion LUNG-1 trial evaluating HERNEXEOS® (zongertinib tablets) in treatment-naïve patients with advanced HER2 (ERBB2)-mutant ...

Ingelheim, Germany / Ridgefield, Connecticut, U.S.Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients ...